![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 34
Zeitschriftenartikel
Raschzok, Nathanael; Stintzing, Sebastian; Heinemann, Volker; Rauch, Geraldine; Ricke, Jens; Guckenberger, Matthias; Kurreck, Annika; Alig, Annabel H. S.; Stahler, Arndt; Bullinger, Lars; Schmelzle, Moritz; Schoening, Wenzel; Lurje, Georg; Krenzien, Felix; Haase, Oliver; Rau, Beate; Gebauer, Bernhard; Sauer, Igor M.; Pratschke, Johann und Modest, Dominik P.
(2022):
FIRE-9-PORT/AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
In: BMC Cancer, Bd. 22, Nr. 1, 359
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Heinrich, Kathrin; Held, Swantje; Stahler, Arndt; Alig, Annabel Helga Sophie; Jelas, Ivan; Einem, Jobst C. von; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2022):
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
In: Frontiers in Oncology, Bd. 12, 751453
Arends, Christopher Maximilian; Dimitriou, Savvina; Stahler, Arndt; Hablesreiter, Raphael; Strzelecka, Paulina M.; Stein, Catarina M.; Tilgner, Marlon; Saiki, Ryunosuke; Ogawa, Seishi; Bullinger, Lars; Modest, Dominik P.; Stintzing, Sebastian; Heinemann, Volker und Damm, Frederik
(2022):
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
In: Blood, Bd. 139, Nr. 10: S. 1593-1597
Sommerhauser, Greta; Kurreck, Annika; Beck, Alexander; Fehrenbach, Uli; Karthaus, Meinolf; Fruehauf, Stefan; Graeven, Ullrich; Mueller, Lothar; Koenig, Alexander O.; Weikersthal, Ludwig F. v.; Goekkurt, Eray; Haas, Siegfried; Stahler, Arndt; Heinemann, Volker; Held, Swantje; Alig, Annabel H. S.; Kasper, Stefan; Stintzing, Sebastian; Trarbach, Tanja und Modest, Dominik P.
(2022):
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
In: European Journal of Cancer, Bd. 178: S. 37-48
Stahler, Arndt; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Kurreck, Annika; Heinrich, Kathrin; Giessen-Jung, Clemens; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian und Heinemann, Volker
(2022):
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
In: European Journal of Cancer, Bd. 173: S. 194-203
Fischer, Laura E. 
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
Hofmann, Felix O. ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
Stahler, Arndt; Heinemann, Volker; Schuster, Veronika; Heinrich, Kathrin; Kurreck, Annika; Giessen-Jung, Clemens; Weikersthal, Ludwig Fischer von; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Kumbrink, Jorg; Stintzing, Sebastian und Modest, Dominik P.
(2021):
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
In: European Journal of Cancer, Bd. 157: S. 71-80
Heinrich, Kathrin; Modest, Dominik P.; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Graeven, Ullrich; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Giessen-Jung, Clemens; Stahler, Arndt; Michl, Marlies; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian und Heinemann, Volker
(2021):
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
In: European Journal of Cancer, Bd. 147: S. 128-139
Liu, Lian; Erickson, Nicole Tonya; Ricard, Ingrid; Weikersthal, Ludwig Fischer von; Lerch, Markus M.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Hoeffkes, Heinz-Gert; Moehler, Markus; Gesenhues, Alena Britta; Theurich, Sebastian; Michl, Marlies; Modest, Dominik P.; Alguel, Hana; Stintzing, Sebastian; Heinemann, Volker und Holch, Julian W.
(2021):
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
In: International Journal of Cancer, Bd. 150, Nr. 1: S. 112-123
Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik P.; Ricard, Ingrid; Giessen-Jung, Clemens; Kapaun, Christine; Ivanova, Boryana; Kaiser, Florian; Fischer von Weikersthal, Ludwig; Moosmann, Nicolas; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Held, Swantje; Decker, Thomas; Moehler, Markus; Neumann, Jens; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
In: Clinical Cancer Research, Bd. 26, Nr. 24: S. 6559-6567
Schulz, Christoph; Heinemann, Volker; Heinrich, Kathrin; Haas, Michael; Holch, Julian W.; Fraccaroli, Alessia; Held, Swantje; Einem, Jobst C.von; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Jung, Andreas und Stintzing, Sebastian
(2020):
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
In: Anti-Cancer Drugs, Bd. 31, Nr. 8: S. 856-865
Stahler, Arndt; Stintzing, Sebastian; Einem, Jobst C. von; Westphalen, Christoph B.; Heinrich, Kathrin; Kraemer, Nicole; Michl, Marlies; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Moehler, Markus; Kaiser, Florian; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
In: European Journal of Cancer, Bd. 137: S. 250-259
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2020):
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
In: European Journal of Cancer, Bd. 137: S. 81-92
Froelich, Matthias F.; Petersen, Elina L.; Heinemann, Volker; Noerenberg, Dominik; Hesse, Nina; Gesenhues, Alena B.; Modest, Dominik P.; Sommer, Wieland H.; Hofmann, Felix O.; Stintzing, Sebastian und Holch, Julian W.
(2020):
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
In: Clinical Colorectal Cancer, Bd. 19, Nr. 4: S. 291-300
Modest, Dominik P.; Martens, Uwe M.; Riera-Knorrenschild, Jörge; Greeve, Jobst; Florschuetz, Axel; Wessendorf, Swen; Ettrich, Thomas; Kanzler, Stephan; Noerenberg, Dominik; Ricke, Jens; Seidensticker, Max; Held, Swantje; Buechner-Steudel, Petra; Atzpodien, Jens; Heinemann, Volker; Seufferlein, Thomas; Tannapfel, Andrea; Reinacher-Schick, Anke C. und Geissler, Michael
(2019):
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
In: Journal of Clinical Oncology, Bd. 37, Nr. 35
Einem, Jobst Christian von; Guenther, Christine; Volk, Hans-Dieter; Gruetz, Gerald; Hirsch, Daniela; Salat, Christoph; Stoetzer, Oliver; Nelson, Peter J.; Michl, Marlies; Modest, Dominik P.; Holch, Julian W.; Angele, Martin; Bruns, Christiane; Niess, Hanno und Heinemann, Volker
(2019):
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial.
In: International Journal of Cancer, Bd. 145, Nr. 6: S. 1538-1546
Froelich, Matthias F.; Heinemann, Volker; Sommer, Wieland H.; Holch, Julian W.; Schöppe, Franziska; Hesse, Nina; Baumann, Alena B.; Kunz, Wolfgang G.; Reiser, Maximilian F.; Ricke, Jens; D'Anastasi, Melvin; Stintzing, Sebastian; Modest, Dominik P.; Kazmierczak, Philipp M. und Hofmann, Felix O.
(2018):
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
In: European Radiology, Bd. 28, Nr. 12: S. 5284-5292
Modest, Dominik P.; Denecke, Timm; Pratschke, J.; Ricard, Ingrid; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, Markus; Seehofer, Daniel; Bruns, Christiane J.; Gebauer, B.; Modest, H. I.; Held, S.; Folprecht, Gunnar; Heinemann, Volker und Neumann, Ulf Peter
(2018):
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
In: European Journal of Cancer (EJC), Bd. 88: S. 77-86
Hofmann, Felix O.; Holch, Julian W.; Heinemann, Volker; Ricard, Ingrid; Reiser, Maximilian F.; Baumann, Alena B.; Hesse, Nina; D'Anastasi, Melvin; Modest, Dominik P.; Stintzing, Sebastian und Sommer, Wieland H.
(2018):
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
In: European Journal of Radiology, Bd. 100: S. 124-129
Winter, Katharina S.; Hofmann, Felix O.; Thierfelder, Kolja M.; Holch, Julian W.; Hesse, Nina; Baumann, Alena B.; Modest, Dominik P.; Stintzing, Sebastian; Heinemann, Volker; Ricke, Jens; Sommer, Wieland H. und D'Anastasi, Melvin
(2018):
Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.
In: European Radiology, Bd. 28, Nr. 11: S. 4839-4848
Holch, Julian W.; Ricard, Ingrid; Stintzing, Sebastian; Modest, Dominik P. und Heinemann, Volker
(Januar 2017):
The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials.
In: European Journal of Cancer, Bd. 70: S. 87-98
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
Einem, Jobst C. von; Peter, Sylvia; Günther, Christine; Volk, Hans-Dieter; Gürtz, Gerald; Salat, Christoph; Stötzer, Oliver; Nelson, Peter J.; Michl, Marlies; Modest, Dominik P.; Holch, Julian W.; Angele, Martin; Bruns, Christiane; Niess, Hanno und Heinemann, Volker
(2017):
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1-a phase I, first in human, first in class trial.
In: Oncotarget, Bd. 8, Nr. 46: S. 80156-80166
Modest, Dominik P.; Denecke, Timm; Pratschke, J.; Ricard, Ingrid; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Modest, H. I.; Held, S.; Folprecht, Gunnar; Heinemann, Volker und Neumann, Ulf Peter
(2017):
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
In: European Journal of Cancer, Bd. 88: S. 77-86
Modest, Dominik P.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C. B.; Holch, Julian W.; Einem, J. C. von; Held, S. und Heinemann, Volker
(2017):
Evaluation of survival across several treatment lines in
metastatic colorectal cancer: analysis of the FIRE-3 trial (AIO KRK0306).
In: European Journal of Cancer, Bd. 84: S. 262-269
Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; Einem, Jobst von; Kirchner, Thomas; Jung, Andreas und Modest, Dominik P.
(2017):
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
In: Anti-cancer drugs, Bd. 28, Nr. 7: S. 717-722
[PDF, 422kB]
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434
Gamba, Sebastian; Camaj, Peter; Heinemann, Volker; Laubender, Rüdiger P.; Wang, Yan; Zhao, Yue; Stintzing, Sebastian; Giessen, Clemens; Boeck, Stefan; Haertl, Christoph; Bruns, Christiane J. und Modest, Dominik P.
(2015):
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
In: Anti-Cancer Drugs, Bd. 26, Nr. 4: S. 371-378
[PDF, 251kB]
Modest, Dominik P.; Schulz, Christoph; Fischer von Weikersthal, Ludwig; Quietzsch, Detlef; Einem, J. C. von; Schalhorn, Andreas; Vehling-Kaiser, Ursula; Laubender, Rüdiger P.; Giessen, Clemens; Stintzing, Sebastian und Heinemann, Volker
(2014):
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
In: Anticancer Drugs, Bd. 25, Nr. 2: S. 212-218
[PDF, 442kB]
Stintzing, Sebastian; Fischhaber, Doris; Mook, Charlotte; Modest, Dominik P.; Giessen, Clemens; Schulz, Christoph; Haas, Michael; Böck, Stefan; Michl, Marlies; Stemmler, Joachim; Laubender, Ruediger P. und Heinemann, Volker
(Oktober 2013):
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
In: Anti-Cancer Drugs, Bd. 24, Nr. 9: S. 969-974
[PDF, 372kB]
Modest, Dominik P.; Brodowicz, Thomas; Stintzing, Sebastian; Jung, Andreas; Neumann, Jens; Laubender, Ruediger P.; Ocvirk, Janja; Kurteva, Galina; Papai, Zsuzsanna; Knittelfelder, Regina; Kirchner, Thomas; Heinemann, Volker und Zielinski, Christoph C.
(2012):
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials.
In: Oncology, Nr. 5: S. 241-247
[PDF, 200kB]
Reinacher-Schick, Anke; Schulmann, Karsten; Modest, Dominik P.; Bruns, Nina; Graeven, Ulrich; Jaworska, Malgorzata; Greil, Richard; Porschen, Rainer; Arnold, Dirk; Schmiegel, Wolff und Tannapfel, Andrea
(2012):
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
In: BMC Cancer
12:349
[PDF, 502kB]